In the lead-up to the 2022 federal election, a decision made within the walls of the health minister's office had far-reaching consequences for millions of Australians. This decision, which locked in a pricing agreement for medical devices, has since become a controversial topic, with critics arguing that it benefits industry at the expense of patients and the wider community.
The Costly Conundrum
The Prescribed List, a little-known schedule, dictates the prices private health funds must pay for over 10,000 medical devices. These prices are often significantly higher than those in public hospitals, leading to a situation where privately insured Australians pay up to three times more for the same surgical hardware.
What makes this particularly fascinating is the intricate web of interests at play. On one side, you have medical device manufacturers, who argue that the premiums charged by private insurers are excessive and that any price drops are not passed on to consumers. On the other, you have private health insurers, who claim that they are not the ones profiting from these high prices, but rather, it's the device companies and private hospitals that are reaping the benefits.
A Question of Balance
The current system, critics argue, is skewed in favor of industry. It isolates medical device manufacturers from normal commercial competition, allowing them to set prices without the usual market forces at play. This, in turn, leads to a legal transfer of wealth from private health insurance policyholders to multinational device companies.
From my perspective, this raises a deeper question about the role of government in regulating such industries. Should the government intervene to ensure a more balanced approach, or should it let market forces dictate prices?
The Political Angle
Interestingly, both major political parties have supported this agreement, despite concerns raised by federal bureaucrats. Mark Butler, the current health minister, endorsed the deal, even though his department advised against it, stating that it primarily benefited industry.
This political support, or lack thereof, for such agreements is a critical aspect of the debate. It suggests that there might be a lack of political will to address this issue, leaving consumers at the mercy of industry interests.
International Benchmarks
A review of the agreement found that while prices for medical devices had fallen, total outlays remained high. This is partly attributed to hospitals using more devices per procedure.
What many people don't realize is that this issue is not unique to Australia. International benchmarking reveals severe price gaps between Australia and other health systems, such as those in New Zealand, Britain, and France. For example, the private Prescribed List benefit for an implanted cardiac defibrillator was $36,500 in 2023, while public hospitals paid $14,500 for the same device.
A Way Forward
The latest review of the Prescribed List agreement recommends that the Australian government urgently review the role of international benchmarking in benefit setting. This suggests that there is an acknowledgment that Australian device prices are artificially high compared to overseas markets.
Personally, I believe that this is a step in the right direction. By comparing prices with other countries, Australia can ensure that its medical device prices are fair and reasonable, benefiting both consumers and the healthcare system as a whole.
In conclusion, the obscure Prescribed List has become a symbol of the complex interplay between industry, government, and consumers in the healthcare sector. It highlights the need for a balanced approach that considers the interests of all stakeholders, ensuring that Australians receive the best possible healthcare without being burdened by excessive costs.
